My major research interest is inflammation and the impact that it has on tissue injury and repair of injury. Most of my work involves studies of inflammation and ulceration in the gastrointestinal tract, although I also have a long-standing interest in cardiovascular inflammation and platelet function. I am particularly interested in identification of novel targets for anti-inflammatory therapies, and the subsequent development of such therapies. I was a co-founder of NicOx, a company based in France which is developing nitric oxide-releasing derivatives of several classes of drugs (see www.nicox.com
). More recently, I founded Antibe Therapeutics Inc., which has offices in Calgary and Toronto (see www.antibethera.com
) and is developing hydrogen sulfide-releasing derivatives of drugs for inflammatory bowel disease, arthritis, irritable bowel syndrome and endothelial dysfunction.